Login to Your Account


Omeicos takes a novel route to tackling chronic atrial fibrillation

By Cormac Sheridan
Staff Writer

Wednesday, November 8, 2017

BERLIN – Omega-3 fatty acids have long been considered to have cardioprotective effects, but Berlin-based Omeicos Therapeutics GmbH has zeroed in on a short-lived metabolite which actually mediates the effect in an effort to develop a drug that can tackle chronic atrial fibrillation, a condition that affects millions of people.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription